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Abstract
Neutralizing antibodies (NAb) able to react to heterologous viruses are generated during natural HIV-1 infection in some
individuals. Further knowledge is required in order to understand the factors contributing to induction of cross-reactive
NAb responses. Here a well-established model of experimental pathogenic infection in cynomolgus macaques, which
reproduces long-lasting HIV-1 infection, was used to study the NAb response as well as the viral evolution of the highly
neutralization-resistant SIVmac239. Twelve animals were infected intravenously with SIVmac239. Antiretroviral therapy
(ART) was initiated ten days post-inoculation and administered daily for four months. Viral load, CD4
+ T-cell counts, total IgG
levels, and breadth as well as strength of NAb in plasma were compared simultaneously over 14 months. In addition, envs
from plasma samples were sequenced at three time points in all animals in order to assess viral evolution. We report here
that seven of the 12 animals controlled viremia to below 10
4 copies/ml of plasma after discontinuation of ART and that this
control was associated with a low level of evolutionary divergence. Macaques that controlled viral load developed broader
NAb responses early on. Furthermore, escape mutations, such as V67M and R751G, were identified in virus sequenced from
all animals with uncontrolled viremia. Bayesian estimation of ancestral population genetic diversity (PGD) showed an
increase in this value in non-controlling or transient-controlling animals during the first 5.5 months of infection, in contrast
to virus-controlling animals. Similarly, non- or transient controllers displayed more positively-selected amino-acid
substitutions. An early increase in PGD, resulting in the generation of positively-selected amino-acid substitutions, greater
divergence and relative high viral load after ART withdrawal, may have contributed to the generation of potent NAb in
several animals after SIVmac239 infection. However, early broad NAb responses correlated with relatively preserved CD4
+ T-
cell numbers, low viral load and limited viral divergence.
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Introduction
The design of an HIV-1 envelope (Env) immunogen capable of
inducing broadly reactive neutralizing antibodies (NAb) has so far
proven extremely difficult. Although NAb directed against Env
can be detected early in infection in a majority of patients, this
antibody response is generally not able to neutralize heterologous
viruses [1–4]. However, some HIV-1 infected patients eventually
develop broadly reactive NAb capable of neutralizing several
different viral isolates [5–9]. Such development of NAb responses
has been associated with long-term non-progression [10–12],
whilst loss of neutralizing activity has been associated with
progression of disease [12,13]. Although the relative contribution
of NAb to prevent progression to AIDS is still unclear [6,7], the
induction of broadly NAb directed against HIV-1 through
vaccination is considered to represent a milestone for the
development of HIV-1 vaccines [14]. This view is supported by
proof-of-concept studies that demonstrated protection against
simian immunodeficiency virus (SIV) with a human immunode-
ficiency virus type 1 envelope (SHIV) through the passive
administration of antibodies with cross-neutralizing capacity
[15–23]. Recently, broad and potent (high-titer) NAb were
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algorithm for characterization of the NAb response was provided
[9]. However, further knowledge is still required to understand
how the immune system may generate cross-reactive NAb
responses against HIV-1. Factors contributing to the elicitation
of broadly NAb may include the magnitude and duration of viral
replication, the preservation of CD4
+ T cells, the degree of B-cell
depletion, the conformation of Env during primary infection, or
the appearance of certain envelope structures during infection
[14]. Addressing these factors in patients is difficult as the sequence
of the founder virus and the time and dose of infection are usually
unknown. In addition, patients can be infected with different
strains of viruses [24].
The SIV/SHIV macaque model has been extensively used as a
surrogate for HIV-1 infection to study pathogenesis, and test
vaccine candidates or novel therapeutics [25]. Infection with a
characterized strain of SIV enables studies of disease progression
in conjunction with the viral evolution and generation of antibody
responses in macaques. Inoculation with SIV or SHIV viruses can
result in induction of NAb. However the high degree of viral
diversity generated in vivo very often leads to antigenic escape
variants and a high replication rate in the macaques [26–28].
Earlier studies have described the evolution of SIV by the use of
comparative techniques; essentially quantifying amino-acid substi-
tutions in small numbers of viruses cloned from different individuals
and compared to a consensus sequence [29]. However, it has since
become clear from longitudinal studies of within-host HIV-1 [30]
and hepatitisCvirus[31]evolutionthat keyevolutionaryparameters
as measured at the within-host level (for instance evolutionary rate)
differ from estimates obtained at the host-population level (by
sampling different individuals). Thus, better understanding of HIV/
SIV evolution strongly highlighted the importance of sampling viral
diversity over time as well as in different hosts in order to accurately
describe viral sequence evolution.
Furthermore, previous comparative studies of consensus
sequences [32] ignored the loss of statistical independence due
to shared phylogenetic ancestry [33]. Thus, viral genetic changes
observed among closely-related taxa may represent non-beneficial
mutations that have yet to be filtered out by selection, rather than
key adaptive mutations. However, recently improved phylogenetic
methods allow inference of the strength of positive (diversifying)
and negative (purifying) selection [34] on a site-wise basis as well as
to identify selection pressure variations within genes in several
viruses [35].
Here we have used experimental pathogenic infection in
cynomolgus macaques, a well-established model for long-lasting
HIV-1 infection, in order to study the appearance of NAb as well
as to follow the evolution of the viral population. Twelve
cynomolgus macaques were infected with SIVmac239 and
subjected to early antiretroviral therapy (ART). Early ART has
previously been demonstrated to preserve SIV/HIV-specific
cellular immune responses, which may be beneficial for long-term
control of viremia [36–38]. However, less is known about the
emergence of NAb responses following early ART. As depletion of
CD4
+ T cells occurs early following infection with SIVmac239
[39], treatment with tenofovir was initiated ten days after viral
inoculation. Thereafter ART was provided between 10 days and
four months post-inoculation. We monitored plasma viremia,
CD4
+ T-cell counts and NAb titers throughout the 14 month
study period. In addition, we studied the viral evolution using a
total of 281 full-length env sequences obtained over the course of
the study from plasma samples and viral re-isolates as well as the
inoculate virus.
We demonstrate that early single drug treatment effectively
controlled viremia in nearly all animals (11 out of 12). In addition,
a majority of animals (seven out of 12) maintained good control of
viremia even after therapy withdrawal (defined as below 10
4 viral
copies post-ART throughout the study). Interestingly, the five
macaques that failed to control viremia following ART withdrawal
acquired the V67M and R751G mutations previously reported to
occur in viral escape variants in a rhesus macaque that developed
unusually high titers of NAb against SIVmac239 [40]. We also
report the induction of high NAb titers in all 12 cynomolgus
macaques following infection with SIVmac239 and early treat-
ment with ART. The strength of the NAb response was greater in
the macaques with poor control of viral load, greater divergence in
env and higher numbers of positively-selected sites early in
infection. We therefore conclude that the increase in viral
population genetic diversity, which occurred prior to the increase
in viral load after ART withdrawal, contributed to the overall
strength of the NAb response.
Results
A majority of SIVmac239 infected cynomolgus macaques
subjected to early short-term ART efficiently control
viremia
Twelve animals were inoculated intravenously with SIV-
mac239. Following confirmation of infection, all animals received
daily subcutaneous injections of tenofovir, starting on day 10 for a
period of four months (Figure 1). Plasma viral load, CD4
+ T-cell
counts and plasma samples for measuring NAb were collected on
11 occasions during the 14 month study period (Figure 1, Table 1
and Figure S1). One animal (number 3), which was the smallest in
the group, displayed a high viral load of 9 million copies/ml seven
days after inoculation. Treatment with tenofovir resulted in a 50-
fold reduction in viral load, which was maintained at around
400,000 copies/ml of plasma throughout the study period. This
animal was therefore referred to as non-controller (NC 3). In all
other macaques, viral load fell below the limit of detection of the
viral load assay during tenofovir treatment (Figure 1). Seven
macaques (numbers 2, 4, 6, 7, 9, 10 and 12) were designated long-
term controllers (LC) as they maintained a plasma viral load of
below 10,000 copies/ml following discontinuation of treatment.
The remaining four macaques (numbers 1, 5, 8 and 11) displayed
a progressive increase in viral load post-treatment, with levels
ranging from 10,000 to 1 million copies/ml of plasma and were
thus designated as transient controllers (TC). Statistically signifi-
Author Summary
In a longitudinal study of clinical and evolutionary
responses to transient treatment in 12 experimentally-
infected macaques, subjects show clear stratification into
two groups based on viral load, immunological response,
and evolutionary factors. Subjects that controlled viremia
following withdrawal of treatment developed broadly
neutralizing antibody responses earlier than subjects with
no or transient control of viremia. Moreover, this latter
group of macaques with higher viral loads showed greater
divergence of SIV sequences, greater numbers of positive-
ly-selected amino-acid substitutions and a stronger
neutralizing antibody response. The increase in viral
genetic diversity started at an early stage of infection.
The authors propose that this early phase of evolution is
principally responsible for the later failure to control
viremia and resulted in the development of potent
neutralizing capacity.
Neutralizing Antibodies Induced by SIVmac239
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TC groups starting at 5.5 months after inoculation (p=0.008,
Mann-Whitney non-parametric test and p,0.0001, two-way
repeated measures analysis of variance model).
A marked decline in CD4
+ T-cell counts (more than 20%) was
detected in the peripheral blood seven days after inoculation in all
animals except for macaques 2, 7 and 12, later classified as LC
(Table 1). The decline of CD4
+ T cells generally slowed following
initiation of tenofovir therapy; CD4
+ T-cell counts reached pre-
infection levels in some macaques (Figure S1). Nevertheless, upon
therapy interruption, gradual CD4
+ T-cell decline occurred over
time and was most pronounced in the NC/TC macaques. A
significant difference (p,0.0001) in CD4
+ T-cell counts was found
between the LC and NC/TC groups starting at week 22, which
Figure 1. Viral loads in macaques after SIVmac239 infection. Twelve 4-year-old male Cynomolgus macaques (Macaca fascicularis) were
infected intravenously with pathogenic cell-free SIVmac239. Treatment with tenofovir was started ten days after inoculation and provided by
subcutaneous injections for 16 weeks, as indicated by the shaded area. Viral loads are depicted longitudinally for each animal. Animals 2, 4, 6, 7, 9, 10
and 12 were designated longterm controllers (LC, green), as defined by maintained viral load below 10,000 copies/ml after treatment interruption.
Animals 1, 5, 8 and 11 were designated transient controllers (TC, blue) due to progressive increase of viral load following treatment interruption and
animal 3 non-controller (NC, red) due to persistent high (over 100,000 copies/ml) viral replication throughout the study. Statistically significant
differences were observed between the LC and NC/TC groups with regards to viral load starting from 4.5 months after inoculation (p=0.002, Mann-
Whitney non-parametric test and p,0.0001, two-way repeated measures analysis of variance model).
doi:10.1371/journal.ppat.1001084.g001
Table 1. CD4
+ T-cell changes and IgG content in plasma over time.
Macaque Group* CD4
+ T-cell change (%){ Plasma IgG change (%){
7 days p.i. During therapy After therapy During therapy 5.5–6.5 months p.i. 7.5–8.5 months p.i 10–14 months p.i.
3N C 226.2 211.6 251.5 24.8 80.2 44.7 7.90
1T C 233.1 29.30 253.0 219.0 9.40 26.20 225.6
5T C 234.5 237.1 252.2 14.7 26.4 29.3 37.4
8T C 220.9 10.7 215.0 10.7 50.6 10.4 9.0
11 TC 250.5 2.10 224.9 11.8 14.2 38.0 27.6
2L C 20.0 27.40 239.2 5.20 24.30 1.80 214.3
4L C 233.0 3.20 230.2 7.70 225.3 219.2 28.10
6L C 246.9 228.6 239.7 3.0 13.4 217.7 231.0
7L C 28.10 12.4 29.90 26.40 26.3 213.5 219.0
9L C 237.2 219.1 238.8 24.10 21.4 28.1 226.3
10 LC 241.2 221.8 25.0 21.3 14.2 20.3 1.80
12 LC 17.9 23.1 218.2 19.8 18.2 12.4 27.80
*NC: non-controller, TC: transient controller, and LC: long-term controller.
{CD4
+ T-cell change: was calculated by using the mean value of CD4
+ T-cell counts in a defined period and is expressed as a percentage of CD4
+ T-cell numbers before
inoculation.
Mean of three samples were used during the therapy phase and seven samples after therapy.
{Plasma IgG change: was calculated by using the mean value of IgG in a defined period and is expressed as a percentage of IgG before inoculation.
Mean of three samples were used during the therapy phase and thereafter two samples for each time period.
doi:10.1371/journal.ppat.1001084.t001
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measures analysis of variance model).
Hypergammaglobulinemia is a known hallmark of HIV-1
infection and therefore plasma IgG levels were measured relative
to baseline IgG (Table 1). IgG levels peaked with an 80% increase
at 5.5–6.5 months after inoculation in macaque NC3. Three of the
TC macaques (5, 8, 11) also displayed an increase in IgG levels
with peaks of 37–50% above baseline at 5.5–8.5 months post-
inoculation. Neither the LC macaques nor the macaque TC1
displayed markedly elevated IgG levels (.30%) throughout the
study period. After treatment interruption, a significantly greater
increase in plasma IgG level was detected in NC/TC macaques
compared with LC macaques (p=0.018, Mann-Whitney non-
parametric test).
The magnitude of sequence divergence correlates to
viral control
To study SIV evolution, a total of 281 full-length env sequences
were obtained, with a mean of seven sequences per plasma time
point (2, 5.5 and 9 months p.i.; range 2–10) (Table S1) and eight
sequences from the inoculate virus. The level of sequence
divergence between the inoculate strain SIVmac239 and each
analysed sequence was estimated from the phylogeny (units of
expected substitutions per site). Divergence, therefore, is a measure
of how different a given analyzed sequence is from the parental
strain. Mean site-wise Shannon entropy was used to measure
sequence diversity for each macaque at the three time-points.
Macaques were grouped according to their viral control (NC, TC,
LC), and the mean divergence (position of circle on y-axis) and
diversity (size of circles) calculated (Figure 2). The mean
divergence increased significantly over time in the NC macaque
(p,0.01 at both 5.5 and 9 months) while the mean divergence in
TC and LC macaques was significantly greater at 9 months
(p,0.01 and p,0.05, respectively). Significant differences were
also observed between the animal groups at both the 5.5 and 9
month time points (p,0.01), with macaque NC3 displaying the
greatest divergence when compared to the two other groups.
Additionally, mean divergence of TC macaques from SIVmac239
was greater than LC macaques at nine months (p,0.01).
Sequences from macaque NC3 were significantly more diverse
than those of LC and TC macaques at the 5.5 and 9 month time
points (p,0.05 and p,0.01 respectively).
High magnitude neutralizing antibody responses
detected in macaques with high viremia
SIVmac239 is considered to be neutralization-resistant. There-
fore purified IgGs from all 12 macaques were first tested for
neutralization of a SIVsm (SMM-3) strain originally isolated from
a naturally infected sooty mangabey monkey, reported as
neutralization-sensitive [41–43]. The magnitude of responses was
tested by titrating IgG obtained from the 4.5 month post-
inoculation (p.i.) plasma samples. This study revealed high-titer
neutralization against SIVsm (up to 1:10240) (Figure 3A). The
highest titers against SIVsm were detected in macaques NC3 and
TC1, 5, 8 ($1:5120) while the LC group displayed lower titers
(ranging from 1:640 to 1:5120). High–titer neutralization against
the SIVsm-related HIV-2 was also detected (Figure S2A and S2B).
A plasma dilution of 1:2560 was chosen to evaluate the kinetics
of emergence of NAb against SIVsm. This study revealed an early
response (2 months p.i.) already detectable during the treatment
phase in NC/TC macaques 3, 1, 5, 8 and in LC number 4
(Figure 3B). The remaining animals neutralized SIVsm at a titer of
Figure 2. Sequence divergence from SIVmac239 in controller, transient-controller and non-controller macaques. Full-length envs
were isolated and sequenced from 12 macaques at 2, 5.5 and 9 months p.i. with SIVmac239. The level of sequence divergence from the inoculate
strain was estimated from the phylogeny under the CTR+c+I model. For each group of macaques (LC, TC and NC), the mean of divergence (position
of circle centre on y axis) and the mean of diversity (radius) is represented here. Mean divergence increased significantly over time in all macaque
groups (5.5 months: LC p.0.05, TC p.0.05, NC p,0.01; 9 months: LC p,0.05, TC p,0.01, NC p,0.01) as determined by two-sample T-tests (with
Welch approximations for degrees of freedom). Mean divergence differed significantly between groups of macaques at 5.5 months (LC vs NC:
p,0.01; TC vs NC: p,0.01) and 9 months (All groups: p,0.01) p.i. Sequences from macaque NC3 were significantly more diverse than those of LC and
TC macaques at the 5.5 (p,0.05) and 9 (p,0.01) month time points.
doi:10.1371/journal.ppat.1001084.g002
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macaques displayed a significantly greater magnitude of neutral-
ization against SIVsm compared with the LC group (p=0.043,
Mann-Whitney test). IgG from the 4.5 month plasma samples was
also titrated against two additional SIVsm isolates, one known to
be highly neutralization sensitive (SIVsm:C39
sens) and the other
resistant to neutralization (SIVsm:C39
res) [43]. As expected, a
majority of macaques had higher titers against SIVsm: C39sens
than SIVsm: C39res (Table 2). The two highest titers against the
neutralization resistant virus were obtained with IgG (from NC3
and TC8) that strongly neutralized the SIVsm stock as well.
Plasma IgG from all 12 macaques was also titrated against
SIVmac239 and SIVmac251 as well as two HIV-2 isolates and 5
HIV-1 isolates. These studies showed that NAb against both HIV-
2 isolates were present at high titers, whilst the capacity to
neutralize HIV-1 CC30 was achieved with 1:20–80 dilutions,
similar to the titers against SIVmac239 inoculate virus and
SIVmac251 (Table 2). Neutralization against the other HIV-1
isolates SF162, 92UG024, 92Br025 and CC48 were only achieved
with 1:20 dilutions in certain animals (data not shown). The mean
of magnitudes of neutralization was calculated by log transforming
the titers according to the formula described in [9] and applied for
the panel of 8 viruses in Table 2. The NC/TC macaques with
high level of viremia displayed a more potent NAb response
compared with the LC macaques (p=0.048, Mann-Whitney test)
(Table 2 and Figure 3C).
Broad early neutralizing antibody responses in macaques
with controlled viremia
Breadth of neutralization was defined as the number of viruses
neutralized at a titer of 20 in purified IgG samples using the cut-off
$3SD in the standardized neutralization assay. Nine viruses were
included in the panel and IgG from all 12 animals obtained at 6.5
and 14 months p.i. were assessed (Figures 4A and 4B, respectively).
LC macaques displayed an early broad neutralization response
that was significantly higher compared with the NC/TC group at
6.5 months after inoculation (Figure 4A, p=0.03 Mann- Whitney
test). The number of virus isolates neutralized ranged from 2–6 at
this time point. However, the breadth of responses increased over
time in all animals and a significant difference was no longer
detectable at 14 months p.i. (Figure 4B). The broadest NAb
response was detected in macaque LC4 which neutralized all nine
viruses tested. The results indicate an association between control
of viremia and development of a broad NAb response early in
infection.
Emergence of neutralization resistant viruses and potent
antibody maturation in macaques NC3 and TC1
Re-isolation of virus from all animals was attempted at 4.5
months p.i. (two weeks after ART withdrawal) as well as at 9
months p.i. and the NAb response of the purified IgG was
measured against the autologous and inoculate virus in order to
follow the evolution of viral neutralization resistances and
neutralization capacity (Figure 5).
The 4.5 month re-isolates from macaques NC3 and TC1 were
resistant to autologous neutralization (at 5.5 months) although
their IgG effectively neutralized the parental virus SIVmac239
(Figure 5A and 5B). This suggests the emergence of neutralization
resistant variants in these animals. Sequences from re-isolated
viruses (4.5 months p.i.) derived NC3 were therefore compared to
the SIVmac239 inoculate sequence in order to identify potential
amino acid substitutions. In all four clones derived from NC3, a
variety of mutations occurred, including V67M, A417T and
R751G (Figure S3). In contrast, all five re-isolates obtained at 4.5
months p.i. from the LC macaques were neutralized by the
corresponding autologous IgG, even though no neutralizing
Figure 3. Heterologous neutralization of SIVsm. (A) Purified IgG
obtained from plasma samples 4.5 months post-inoculation were
titrated and analyzed for neutralization of SIVsm (SMM-3). Neutraliza-
tion profiles of NC (animal 3, red) and TC (animals 1, 5, 8, 11, blue) as
well as LC (animals 2, 4, 6, 7, 9, 10, 12, green) are shown. Values are
means of two independent assays. Assay cut-off was 30% as indicated
by line. The NC/TC macaques displayed a significantly greater
magnitude of neutralization against SIVsm compared with the LC
group (p=0.043, Mann-Whitney test). (B) Purified IgG corresponding to
1:2560 dilution were analyzed for neutralization of SIVsm in samples
obtained at ten different time points. Tenofovir treatment period is
indicated by shaded area. (C) The potency score for each macaque was
calculated by summarizing the magnitude (neutralization score) against
each virus and then dividing by total number of viruses tested (n=8) as
shown in Table 2. The magnitude of an individual IgG sample was
determined by its neutralization score defined as log-transformed titers.
Log-transformed titers were calculated by dividing the highest
neutralizing titer values by 100 before applying a log-base 3
transformation and then adding 1 [Y=log3 (dilution/100)+1]. The size
of circle corresponds to the potency score. The NC/TC macaques
displayed a significantly greater potency score compared with the LC
group (p=0.048, Mann-Whitney test).
doi:10.1371/journal.ppat.1001084.g003
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SIV HIV-2 HIV-1
Macaque Group* Potency{ SIVsm: SMM-3 SIVsm:C39sens SIVsm:C39res SIVmac239 SIVmac251 1682 1812 CC30
3 NC 4.17 10240 163840 327680 80 80 10240 10240 20
1 TC 2.79 5120 1280 1280 ,20 ,20 10240 20480 ,20
5 TC 3.28 10240 10240 1280 40 20 40960 20480 20
8 TC 4.25 10240 20480 327680 40 ,20 163840 20480 80
11 TC 3.38 1280 81920 640 40 ,20 81920 20480 80
2 LC 3.02 640 40960 1280 20 ,20 40960 10240 20
4 LC 3.20 5120 10240 1280 40 20 81920 10240 20
6 LC 2.86 2560 40960 1280 20 20 5120 5120 20
7 LC 2.23 1280 1280 320 20 20 2560 10240 20
9 LC 3.26 2560 81920 640 20 20 81920 10240 20
10 LC 2.57 640 1280 1280 ,20 ,20 5120 20480 80
12 LC 3.14 2560 40960 640 40 20 81920 2560 80
*NC: non-controller, TC: transient controller, and LC: long-term controller.
The titers correspond to 30% neutralization. The magnitude of response for each macaque IgG is calculated by; log 3(titer/100)+1.
{The potency is mean of the magnitudes for each macaque against the given panel of SIV, HIV-2 and HIV-1 viruses.
The NC/TC macaques with high level of viremia displayed a more potent NAb response compared with the LC macaques (p=0.048, Mann-Whitney test).
doi:10.1371/journal.ppat.1001084.t002
Figure 4. Evolution of neutralization breadth over time. Comparison of neutralization breadth at 6.5 (A) and 14 (B) months post-inoculation.
Color code: NC, red, TC, blue, LC, green Figure denotes % neutralization at 1:20 dilution. SIVsm used was SMM-3. The LC macaques displayed a
significantly greater breadth at 6.5 months compared with the NC/TC group (p=0.03, Mann-Whitney test).
doi:10.1371/journal.ppat.1001084.g004
Neutralizing Antibodies Induced by SIVmac239
PLoS Pathogens | www.plospathogens.org 6 September 2010 | Volume 6 | Issue 9 | e1001084activity against the inoculate SIVmac239 could be detected before
5.5 months in these macaques (Figure 5C and 5D). This could be
explained by the early development of broad NAb responses in LC
macaques as compared to the NC/TC group.
IgG from 8.5–10 months p.i. samples from macaque NC3,
neutralized both the 4.5-months and 9-months re-isolates.
Similarly, the 4.5-months re-isolate from macaque TC1 was
neutralized by IgG obtained from later samples. A likely
explanation for this is affinity maturation of NAb that takes place
over time. It is also possible that the increase in breadth of NAb
response over time has contributed to neutralization of these re-
isolates. It should be noted that this increase of neutralization
capacity did not result in a significant reduction in viral load in
either of the macaques (Figure 1), suggesting that selection of
neutralization resistant variant viruses is a continuous process [1].
Site wise selection analyses show large numbers of
positively-selected mutations in NC and TC animals that
occur early in infection
To differentiate between amino-acid substitutions arising from
neutral evolution and those arising that confer a selective
advantage, we estimated the ratio of non-synonymous to
synonymous nucleotide changes (dN : dS) at individual codons.
The site-wise (dN/dS) analyses were carried out as detailed in the
Methods and corrected for multiple testing using the Benjamini &
Hochberg [44] false discovery method with a critical value of 0.05.
Following correction, 39 sites were found to be under significant
positive (diversifying) selection, where there is an excess of non-
synonymous nucleotide changes. A paucity of nucleotide changes
resulting in codon substitution where synonymous changes were
plentiful suggested a constrained (negatively-selected) site; 49
codons were found to be under significant negative (purifying)
selection at alpha=0.05 (Table S2).
The existence of chains of mutations whose sequential arrival is
replicated in separate individuals is predicted to be a consequence
of evolutionary responses by the virus to selection pressure from
lymphocyte activity (‘escape’ mutations). In order to gain insights
into these sequential amino-acid substitutions, particularly escape
mutations, we took advantage of temporal information in the
phylogeny to reconstruct the earliest time at which each amino-
acid substitution occurred, defined here as the ‘arrival time’ of a
substitution. We therefore compared the estimated arrival time for
all sites predicted to have significantly positively-selected amino-
acid substitutions with the arrival time of appearance for amino-
acid replacements that were not significantly likely to represent
positively-selected sites. A one-way ANOVA determined that the
mean time of first appearance was earlier for positively-selected
substitutions compared to neutrally-selected substitutions. Fur-
thermore, we observed that positively-selected substitutions tended
to occur during or very shortly after the treatment period
(Figure 6). When the earliest estimated arrival of positively-
selected sites are mapped to the phylogeny (Figure S4), it can
clearly be observed that LC macaque sequences exhibit far fewer
positively-selected substitutions than those of NC/TC macaques.
Early increase of viral population genetic diversity
detected in non-controller macaques
In the presence of selection, there is a non-linear relationship
between the absolute size of the viral population (as measured by
Figure 5. Autologous neutralization of SIVmac239. Purified IgG corresponding to 1:20 dilutions were analyzed for neutralization of SIVmac239
in samples obtained at eleven different time points. Tenofovir treatment period is indicated by shaded area. (A) Development of neutralizing plasma
titers against SIVmac239 inoculate in NC3 (3; red) and the 1
st re-isolate (39; pink), (B) in TC macaques against inoculate (dark blue) and reisolates (9;
light blue). (C) and (D) Neutralization against inoculate in LC animals (dark green) and reisolates (9; light green). Values are means of two independent
assays. Assay cut-off was 30% as indicated by line.
doi:10.1371/journal.ppat.1001084.g005
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a large population may be less diverse than a smaller one,
potentially exposing the host immune system to a smaller variety
of antigens [45]. We therefore estimated ancestral population
genetic diversity (PGD) through time. These PGD plots, or
‘skyline’, plots provide a better indication of the variety of
antigens likely to have challenged the host immune system than
diversity or absolute population size alone. As described in the
Methods, substitution model and mean evolutionary rate
parameters were jointly estimated from the combined data set,
since some individual animals’ data sets did not contain sufficient
sampling intensity to allow these parameters to be separately
estimated. Post-hoc rate correction to allow for heterogeneous
mean substitution rates among animals was achieved by scaling
the estimated ancestral PGD plots such that individual animals’
tree mean posterior root heights were equal.
The individual traces for each animal can be seen in Figures 7A
and 7B, which show the PGD trace for the NC3 macaque
superimposed with the mean posterior PGD for TC and LC
groups respectively. The 95% confidence intervals on population
size are shown by the upper and lower bounds on the PGD
traces, while the lower 95% confidence interval on root height
(time of most recent common ancestor) is shown by vertical
dashed lines. It can clearly be seen that LC macaques (2, 4, 6, 7,
9, 10, 12) experience persistently lower and more slowly
increasing population diversity than both TC macaques (1, 5, 8
& 11) and the NC (macaque 3). Furthermore, while PGD levels
were held low during the treatment period for LC macaques (and
viral loads decreased during treatment for all animals, except
NC3), the data suggest that PGD for TC macaques began to
increase before the end of treatment (however we cannot
unambiguously resolve the timing of the PGD increase due to
the large confidence intervals on these estimates.) The NC3
experienced persistently high and increasing population genetic
diversity throughout the study.
The positively-selected mutations are localized in
different regions of gp120 in NC, TC and LC macaques
Positively-selected (Table S2) mutations were analyzed for their
appearance in the three different groups of macaques. Substitu-
tions V67M, A417T, R751G and L802F appeared in macaque
NC3 and in several TC macaques. In contrast none of the LC-
derived viruses carried any of these substitutions. Mutation A417T
results in an additional glycosylation site in V4 domain, previously
found to result in a dramatic increase in neutralization resistance
[40]. Interestingly the L802F, R751G, and V67M substitutions are
associated with increased replicative capacity and are also present
in viruses adapted to macrophages or isolated from the CNS of
infected macaques [46,47].
Statistical support for positive selection was compared between
the entire gene and each hypervariable (V) region in gp120.
Strongest support for evolutionary pressure was found in V1, V2
and V5, with significantly higher eCDF values at p,0.001 and
p,0.05 for V2 (Figure S5). Evolutionary linkage (epistasis) of
positively-selected sites was investigated using a Bayesian graphical
model (Table S3). Analysis of structural proximity in monomeric
and trimeric molecular models of SIV gp120 revealed that the
identified epistatic interactions were not co-localized (data not
shown). Mapping of the selected sites on a molecular model of the
SIVgp120 revealed that positively-selected substitutions tended to
occur on solvent-exposed regions, while most of the putative
trimerisation interface was unaffected (Figures 8A and 8B).
Conversely, the conserved sites including several glycosylation
sites, cysteines, and other structurally important residues such as
the co-receptor binding site were confined to the core of the
monomer.
Substitutions, which we have observed to occur early on and in
greater numbers in NC/TC macaques, differ in the location and
timing of their appearance on gp120 (Figure 8C). A majority of
positively-selected mutations had already appeared by 5.5 months
in macaque NC3 (Figure 8C). Most notably for the NC/TC
Figure 6. Estimated arrival times of amino-acid substitutions. Amino-acid substitutions were tracked through the whole phylogeny by
estimating ancestral sequences at every internal node. The elapsed time since infection and genotypes of these ancestral sequences were then
compared to estimate the set of first occurrences in any given lineage (‘arrival times’) for each substitution. (A) Box plot of estimated earliest
(minimum) arrival times; (B) Box plot of estimated latest (maximum) arrival times. Sites with p (dN/dS.1)#0.05 (see Methods) were categorised as
‘positively-selected.’ Substitutions at other sites were therefore assumed to have occurred neutrally.
doi:10.1371/journal.ppat.1001084.g006
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the V1/V2, V4 and V5 loops on the outer face of gp120 known to
be important in antibody escape. V67M appeared in a solvent-
exposed region of gp120 potentially interacting with gp41. Two
additional positively-selected sites (K254 and V260) also appeared
in proximity to V67M in both TC and LC macaques. The
observed differences in positions of positively-selected mutations
further indicate differences in gp120 evolution between the three
groups of macaques. In particular, the appearance of V67M and
A417T, present in NC/TC macaques, may play an important role
in the observed viral load and/or NAb responses.
Multivariate correlation between evolutionary and
clinical factors
In order to determine whether any correlation existed between
the sequence evolution and clinical measurements, a multivariate
rank sum analysis was performed which compared all variables
with each other and identified correlations in the data set. Due to
lack of normality in some of the data set we opted to perform a
non-parametric analysis of ranked data. The results of the
neutralization assays were combined to give ranks for NAb
potency, NAb breadth at 6.5 months, and NAb breadth at 14
months. Additional measures included: neutralizing titer against
SIVsm, viral load at 6.5 months, and decline of CD4
+ T cells by
6.5 months as well as CD4
+ T-cell counts at 6.5 months. Key
evolutionary parameters analysed were mean sampled diversity
per animal, divergence from the inoculate strain as estimated by
maximum likelihood reconstruction, the number of positively-
selected amino-acid substitutions observed at p,0.05, and the
integral of mean estimated PGD over the treatment period as well
as the total study period. The correlation table is shown in (Table 3)
with positive correlations (following correction for false discovery
rate at alpha=0.05) marked in bold.
Both sequence divergence and the number of positively-selected
mutations correlated with the potency of the NAb response
(p=0.033 and p=0.015, respectively). Additionally, a high viral
load correlated with a greater number of positively-selected
mutations (p=0.010), as previously observed when comparing
LC and NC/TC macaques. The NAb SIVsm titer correlated with
both sequence divergence (p=0.031) and the number of positively-
selected mutations (p=0.012) as well as the overall potency
(p=0.019). In terms of the breadth of NAb response, CD4
+ T-cell
count at 6.5 months correlated with the NAb breadth at that time
(p=0.036), whilst breadth at 14 months correlated with the PGD
over duration of entire study period (p=0.022). The integral of
mean PGD during the treatment period was close to being
significantly associated with late breadth responses (p=0.059). It
therefore appears that LC macaques, with higher CD4
+ T-cell
count, have a broader NAb response at the intermediate time
point of 6.5 months but by 14 months the NC/TC macaques, with
early high PGD, show greater NAb breadth. Furthermore, the
increased sequence divergence observed in the NC/TC macaques
Figure 7. Viral population genetic diversity through time (‘skyline plots’) of individual infections. Skyline plots were obtained through
BEAST and show the estimated viral population genetic diversity (PGD) through time. (A) Median posterior PGD of LC animals (2, 4, 6, 7, 9, 10 & 12;
dashed green lines); mean median PGD of the set of all LC animals (brown line) and maxima and minima of upper and lower 95% confidence intervals
for the set (shaded green area). A much larger median posterior PGD was estimated for animal 10 than for the other LC animals; this is marked with
an asterisk (*). However the 95% confidence intervals for this animal were also largest in the LC group. (B) Median posterior PGD of TC animals (1, 5, 8
& 11; dashed blue lines); mean median PGD of the set of all TC animals (brown line) and maxima and minima of upper and lower 95% confidence
intervals for the set (shaded blue area). Both plots: NC (animal 3) median PGD (thick red line) and upper and lower 95% confidence intervals (shaded
red area). The shaded yellow area covers the treatment period. In all plots post-hoc rate correction was employed to scale the PGD on the time axis
(see Methods).
doi:10.1371/journal.ppat.1001084.g007
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inner domain of the monomer is displayed in dark grey. Positively- and negatively-selected mutations are highlighted as orange and cyan spheres,
respectively. (A) Combined analysis of the localization of the positively- and negatively-selected mutations found at 2, 5.5 and 9 months. The gp120
monomer is oriented with the V3 domain pointing away from the viewer. In contrast to the conserved sites that are mostly localized within the core
of the monomer, the positively-selected mutations are predominantly exposed on the surface of gp120. (B) The selected mutations are highlighted in
a molecular model of the gp120 trimer viewed with the same orientation as in 8A (left) or ‘from the side’ following a 90u rotation (right). (C)
Progressive and clustered appearance of the positively-selected mutations analyzed individually for each of the three different monkey groups LC, TC
and NC at 2, 5.5 and 9 months. The inner and outer as well as the V1/V2 and V3 domains are indicated. The orientation of the monomer was slightly
tilted with respect to (B) and the occurrences and localizations of the V67M and A417T mutations are highlighted.
doi:10.1371/journal.ppat.1001084.g008
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the LC macaques.
Discussion
This study represents the most comprehensive longitudinal
analyses to date on the appearance of broad and potent NAb
responses in the context of viral evolution in 12 experimentally-
infected macaques subjected to transient ART. Twelve cynomol-
gus macaques were inoculated with pathogenic SIVmac239. In
order to preserve CD4
+ T-cell counts, tenofovir was administered
daily between 10 days and four months post-inoculation. Eleven
out of twelve animals controlled viral loads during treatment.
However, on cessation of therapy the transient controller (TC
n=4) group immediately experienced increased viral loads. Not
unexpectedly the decline in CD4
+ T-cell count was tightly
correlated to the plasma viral load and was therefore slower in
long-term controller (LC n=7) macaques when compared to NC/
TC animals.
A striking feature of our results is a discrepancy between viral
population genetic diversity and viral loads over time, in the TC
and LC groups. In both TC and LC animals, viral loads were
controlled during treatment; only after treatment did their viral
loads diverge, as the TC animals failed to control viremia and their
viral loads increased. Although we had no direct measurements of
viral diversity over the treatment period, we were able to use
evolutionary analysis to infer PGD during this time. Crucially, and
despite the low viral load seen in TC animals, we found that PGDs
of TC animals not only tended to exceeded those of LC animals
later in the study period, but also seemed to increase earlier.
Although our results do not offer enough precision to definitively
date the increase in PGD in every animal, it seems likely that this
early increase in PGD in TC animals compared with LC animals
occurs in the first 5 months.
This difference in evolutionary behaviour is repeated in the
selected-sites analysis. TC macaques show a large number of
positively-selected amino-acid replacements compared with LC
animals; furthermore these substitutions occurred earlier than
neutrally-selected substitutions. Mapping of the spatial location of
the positively-selected codons to predicted gp120 structures
indicated that these were located in solvent-exposed sites on the
surface of the molecule, similar to data reported previously for
HIV-1 gp120 [48,49].
These differences in evolutionary dynamics between groups
were also evident in the observed distributions of substitutions;
V67M, and R751G appeared in all NC/TC macaques but none
of the LC-derived viruses. In addition, mapping of these
substitutions to the phylogenetic tree indicated that they had
occurred early following infection. The R751G and V67M
substitutions are associated with increased replicative capacity
but the precise mechanisms remain to be determined [46].
Evolutionary theory predicts that population genetic diversity is
directly proportional to population size only in the absence of
selection. If this were true, then the greater diversity seen at later
Table 3. Multivariate correlation between evolutionary and clinical factors.
Viral
Load
Mid
a
Breadth
Mid
a
Breadth
Late
b Potency
c Divergence
d Diversity
e
CD4
Decline
f
CD4
Count
g
No. pos
sites
h
Neut
SIVsm:
SMM-3
i
PGD
Treatment
j
PGD
All
k
Viral Load
Mid
0.992 0.287 0.060 0.347 0.764 0.867 0.996 0.010* 0.104 0.662 0.347
Breadth
Mid
0.426 0.658 0.605 0.183 0.151 0.036* 0.976 0.819 0.486 0.251
Breadth
Late
0.819 0.819 0.336 0.120 0.353 0.562 0.749 0.059 0.022*
Potency 0.033* 0.338 0.727 0.928 0.015* 0.019* 0.610 0.399
Divergence 0.066 0.679 0.895 0.116 0.031* 0.364 0.509
Diversity 0.778 0.792 0.426 0.621 0.208 0.472
CD4 Decline 0.017* 0.914 0.935 0.123 0.463
CD4 Count 0.979 0.889 0.222 0.771
No. pos. sites 0.012* 0.662 0.523
Neut SIVsm:
SMM-3
0.685 0.220
PGD
Treatment
0.338
PGD All
Macaques 1–12 were assigned ranks based on clinical and evolutionary parameters. Corrected p values are given where p,0.05 indicates statistical significance*.
aMid=6.5 months p.i.
bLate=14 months p.i.
cThe potency is the mean of the magnitudes for each macaque against SIV, HIV-2 and HIV-1 shown in Table 2.
dMean sequence divergence from SIVmac239 over all time points, estimated under CTR+c+I.
eMean diversity as determined by mean site-wise Shannon entropy in each subject sequence alignment over all time points.
fDecline in CD4
+ T-cell numbers from start of study to 6.5 months p.i.
gTotal CD4
+ T-cell count at 6.5 months.
hTotal number of positively-selected sites in each subject’s sequences.
iNAb SIVsm:SMM-3 titer 4.5 months p.i.
jIntegral of PGD during treatment period.
kIntegral of PGD over duration of study.
doi:10.1371/journal.ppat.1001084.t003
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increase in viremia in these animals, rather than its cause.
However, at early time-points, our results strongly suggest that TC
and NC viral populations have diversified whilst viral loads were
low, a dynamic that can be explained by the generation of
positively-selected amino-acid substitutions, which leads to greater
population genetic variation and allows virus to escape immune
control. Positive selection in viral populations is documented to
occur in response to selection pressures by the host immune system
and from treatment [50]. In this analysis; treatment, cytotoxic T
cells and NAb activities may all have exerted selection pressures on
the virus.
Within 2 months p.i. NAb active against SIVsm (strain SMM-3)
were already detected in the NC/TC group of macaques.
Neutralizing titers against SIVsm exceeded 1:640 in all macaques
by 4.5 months p.i. (2.5 months post-ART cessation) and reached
levels as high as 1:10240 in three macaques. Even though a
heterologous NAb response against SIVmac251 and SIVdel-
taB670 has previously been documented in SIVmac239 infected
macaques [51,52] and a response against SIVsm was expected due
to its close phylogenetic relationship to SIVmac239 [45],
neutralizing activity at such an early time point and of such high
magnitude has not been reported before. However, the inoculate
virus SIVmac239 could only be neutralized by IgG isolated after
5.5–7.5 months p.i. in the majority of animals. It therefore seems
that prolonged exposure of the immune system to viral antigen is
necessary in order to evoke NAb responses to SIVmac239.
The emergence of broadly cross-neutralizing antibodies in
macaques at 6 to 8 months p.i. has previously been demonstrated
[51,52]. Our results support and extend these findings as we
demonstrate the generation of broad NAb towards different SIV,
HIV-2 and HIV-1 within 6 to 8 months. Antibody responses
undergo complex maturation over time involving progressive
changes in antibody avidity and conformational dependence
[51,52]. Antiretroviral treatment of macaques within this study has
apparently impaired SIVmac239 replication capacity to levels
corresponding to attenuated SIV strains used by Cole et al [52]
resulting in a similarly long period (6–8 months) of affinity
maturation. Hence, the findings presented here support the
suggestion that time since infection and the presence of low to
moderate viremia are factors contributing to the development of
broadly reactive NAb [7,8,53].
Interestingly, the quality of NAb response, as reflected by
breadth and potency, varied with the severity of SIV infection.
Accordingly, viral control was associated with early development
of broadly reactive NAb, whereas no or transient viral control was
associated with higher potency. In addition, our findings provided
insight as to the role of viral evolutionary factors contributing to
the development of NAb activities. Analysis of sequence
divergence from the inoculate strain revealed statistically signifi-
cant differences between NC, TC and LC macaques. Viruses in
plasma of NC3 accumulated a large number of amino acid
mutations in env, reflected by a high level of divergence from
SIVmac239. Divergence increased over time and also differed
between all groups of macaques (NC, TC and LC) at 9 months p.i.
NC/TC macaques showed greater levels of sequence divergence
than LC macaques and the data suggest that PGD started to
increase during the first 5 months in the NC/TC macaques.
Therefore, we propose that the increase in viral divergence and
diversity preceded the increase in viral load, and subsequently
contributed to the strengthening and broadening of the NAb
responses. Stratification of macaques into three distinct groups
may bias outcomes when looking for associations. Therefore,
macaques were ranked according to different functional param-
eters and viral characteristics and a multivariate analysis
conducted. A Spearman’s rank correlation determined that viral
divergence in these macaques is strongly positively correlated with
potency of the NAb responses. In macaques with more divergent
viruses, the immune system has been exposed over time to a
greater diversity of viral envelopes. Such diversity combined with
appropriate antigen load may contribute to the overall magnitude
NAb response.
Taken together, our results indicate that the macaques that
controlled viral load displayed limited divergence, few positively-
selected substitutions, slower CD4
+ T-cell decline, and slower and
less marked increase in PGD. Early on, they developed a broad
NAb response although of limited potency, as compared to the
transient controller group. Transient controller macaques, on the
other hand, with higher viral loads later on, showed higher
numbers of positively-selected sites, an early increase in PGD and
greater divergence of SIV sequences. This correlated with higher
potency NAb. Therefore, we suggest that the early increase in
PGD preceded the increase in viral load after treatment
withdrawal, subsequently setting the stage for development of
potent NAb in these macaques. These results have implications for
vaccine design and suggest that broad NAb but of low potency can
be induced by relatively low antigen load with limited sequence
diversity. Instead, the development of more potent NAb required
higher diversity of antigens and included higher antigen load.
These results also have implications for antiretroviral treatment
and suggest that the increase in PGD started at an early stage of
infection, either immediately following, or during, the treatment
phase. We propose that this early phase of evolution is principally
responsible for the later failure to control viremia.
Methods
Ethics statement
The animals were housed and handled at the Primate Research
Centre of the Swedish Institute for Infectious Disease Control
(Solna, Sweden) according to directives and guidelines of the
Swedish Board of Agriculture, the Swedish Animal Protection
Agency, The European Council Directive 86/609/EEC, and
Convention ETS 123, including the revised Appendix A. The
study was performed under approval of the Stockholm North
Ethical Committee on Animal Experiments. The animals were
housed in pairs in 4 m
3 cages, enriched to give them the possibility
to express their physiological and behavioural needs. They were
habituated to the housing conditions for more than six weeks
before the start of the experiment, and subjected to positive
reinforcement training in order to reduce the stress associated with
experimental procedures.
Animals
Twelve four-year-old male Cynomolgus macaques (Macaca
fascicularis) of Chinese origin were inoculated intravenously with
8000 MID50 of pathogenic cell-free SIVmac239 grown in rhesus
macaque peripheral blood mononuclear cells (PBMCs) (kindly
provided by Christiane Stahl-Hennig, Go ¨ttingen, Germany). The
animals showed high viremia levels seven days post-inoculation
(p.i.) and were subsequently treated from day 10 with a daily dose
of 30 mg/kg of (R)-9 (2-phosphonylmethoxypropyl) adenine
(PMPA) (tenofovir) given subcutaneously (Gilead Biosciences,
CA, USA) for four weeks [54]. The tenofovir dose was thereafter
reduced to 20 mg/kg and administered for 12 more weeks. The
macaques were monitored for general clinical status, and blood
samples were collected at four/six week intervals for analyses of
viral load, CD4
+ T-cell counts and NAb. The ExaVirLoad kit with
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equivalents) of plasma was used for viral load determinations
according to the manufacturer’s instructions (Cavidi Tech AB,
Uppsala, Sweden) [55]. CD4
+ T-cell percentages and absolute
CD4
+ T-cell counts were analysed by flow cytometry using True
Count tubes and CD45, CD4 and CD8 antibodies (BD
Biosciences). Data was acquired on a FACSCalibur instrument
using Cell Quest software (BD Biosciences).
Viruses used in neutralization assays
SIVmac239 inoculate, SIVsm stock (sooty mangabey, strain
SMM-3 originally obtained from P. Fultz and H. McClure, Yerkes
National Primate Research Center, Atlanta, GA, USA [41,42]),
SIVmac251 [56] and two SIVsm re-isolates from a cynomolgus
macaque, C39, that differed in their sensitivity to neutralization by
autologous and heterologous sera from SIVsm-infected macaques
were used [43]. SF162 (subtype B), 92BR025 (subtype C),
92UG024 (subtype D), CC030 and CC048 (CRF.02_AG) viruses
were chosen as representatives of HIV-1 virus and the 1812 and
1682 viruses represent HIV-2 [57]. Virus stocks were prepared by
infection of human PBMC activated with phytohemagglutinin for
three days, as previously described [58]. Briefly, SIV-infected
PBMC were cultured in RPMI 1640 medium (GIBCO Paisley,
UK) with 10% fetal calf serum (FCS; Hyclone, Argentina), 10,000
IU/ml penicillin-streptomycin (Sigma, St. Louise, MO), 10 units/
ml interleukin-2 (IL-2, Amersham Pharmacia Biotech, Sweden),
and 2 mg/ml polybrene (Sigma, Germany). Cell free supernatants
were collected seven and ten days after infection, aliquot and
frozen at 280uC until use.
Purification of total IgG from plasma
Plasma samples from SIVmac239-infected macaques were
obtained from eleven time points: pre-inoculation, 1, 2, 3.5, 4.5,
5.5, 6.5, 7.5, 8.5, 10 and 14 months p.i. (Figure 1.A). Total
immunoglobulin G (IgG) was used in all neutralization assays. IgG
was purified by a method adapted from Dong et al [59]. In brief,
200 ml Protein G-Sepharose Fast Flow beads (GE Healthcare Bio-
Sciences AB) were added to Eppendorf tubes and washed twice
with 1 ml of sterile PBS. Plasma samples were first inactivated at
56uC for 30 minutes and then centrifuged at 40006g for 20 min.
200 ml plasma and 200 ml PBS were added to the washed Protein
G-Sepharose Fast Flow Beads and the mixture was incubated at
room temperature for 1 h on a tube rotator. Thereafter plasma-
bead mixtures were transferred to 0.45 mm-pore-size cellulose
acetate filter Spin-X tubes (Costar) and centrifuged at 10006g for
1 min, followed by one wash with 600 ml of PBS and finally
centrifuged at 20006g for 5 min to dry the beads. Neutralization
buffer (20 ml, 1 M Tris-HCl, pH 9.0) was added to the bottom of
fresh collection tubes and bound IgG was eluted with elution
buffer (90 ml, 0.1 M glycine-HCl, pH 2.5) and centrifuged at
10006g for 5 min into the neutralization buffer. Elution was
repeated with another 90 ml of elution buffer and centrifuged at
20006g for 5 min. Purified IgGs were kept at 220uC until use.
Yield of IgG was analysed by ELISA [60]. Plates were coated
overnight with AffiniPure goat anti-human IgG (20 mg/ml)
(Jackson Immunotech). Alkaline phosphatase-conjugated anti-
human IgG (diluted to 1:5000) (Jackson Immunotech) was used
as a detection antibody and macaque IgG (Rockland) was used as
a standard. A positive control macaque serum (1YR) was a
generous gift from Dr. Gerrit Koopman (BPRC, The Nether-
lands). Macaque 1YR had been infected by SIV-BK28 (a
molecular clone of SIVmac251) five years earlier and was a
long-term non-progressor [54]. The negative control was prepared
by pooling plasma from three SIV-negative macaques.
Neutralization assay in GHOST(3)-CCR5 cells
The GHOST(3)-CCR5 cell line has been derived from a
human osteosarcoma cell (HOS) line by introducing the human
CD4 gene and a chemokine receptor, here CCR5 [57]. The cells
were also stably transfected with a vector construct encoding the
green fluorescence protein (GFP) driven by the HIV-2ROD LTR.
Upon infection, the viral Tat protein activates the GFP marker
and infected cells show green fluorescence. The GHOST(3)-
CCR5 cell line was maintained in Dulbecco’s modified Eagle’s
medium (DMEM; GIBCO) complemented with 7.5% FCS and
10,000 IU/ml penicillin-streptomycin in 25 cm
2 culture flasks.
The cultures were kept in a humidified atmosphere with 5% CO2
at 37uC. Monolayers were detached with 5 mM EDTA (pH 8.0)
and split twice a week at a ratio of 1:15–20. Cell lines were used for
experiments within two months after thawing.
One day before infection the GHOST(3)-CCR5 cells were
seeded into 96-well plates at a concentration of 5610
3 cells/well in
200 ml medium and incubated overnight at 37uC. Prior to
infection, the medium was replaced with 50 ml fresh medium
containing polybrene (2 mg/ml). Viruses were first titrated in five
5-fold dilution steps on the GHOST(3)-CCR5 cells to determine
an appropriate virus concentration for the neutralization assays
[43]. On the day of infection, virus was first diluted 5-fold in
culture medium, followed by at least four 5-fold dilution steps,
giving dilutions from 1/5 to 1/3125. Each dilution was added to
triplicate wells at a volume of 150 ml per well and cultures were
incubated overnight at 37uC. The day after infection, cultures
were replaced with 200 ml fresh medium. Three days after
infection, cultures were scored for individual numbers of cells or
syncytia showing fluorescence (plaques) by fluorescence microsco-
py. Virus titers were calculated as plaque forming units (PFU) per
ml: (average number of plaques in triplicate wells6virus dilution)/
volume in the well [61]. For neutralization assays, IgG fractions of
plasma and virus were mixed at dilutions that gave a final IgG
concentration corresponding to IgG levels in diluted plasma and a
virus concentration that gave between 10–90 fluorescent plaques
per well. The virus and IgG mixtures were incubated at 37uC for
one hour and subsequently titrated in triplicate (150 ml/well). The
next day, plates were washed once and fresh medium added. At
day three fluorescent plaques were counted under the fluorescent
microscope. Neutralization was expressed as percentage of plaque
reduction in the sample containing IgG, relative to virus without
sample IgG and calculated using the formula: Plaque reduction
(%)=[12(PFU with sample IgG/PFU without sample IgG)]6100
[43]. Intra-assay variation has been assessed to establish the cut-off
for neutralization to be used in the GHOST(3) assay. The
standard deviation of the GHOST(3) assay range from 9.5% to
9.9% and applying .3SD as the cut-off results in 30%
neutralization as the limit of detection [43,61] and data not
shown. The enhancement effect (Figure 3B) resulted in negative
percentage neutralization values; logistic regression analyses
indicated that the optimal fitting of the neutralization curves gives
a median neutralization value of approximately 30%.
Potency and breadth analysis
For analysis of the magnitude of NAb responses, IgG samples
were titrated and used in neutralization assays against 4 SIV
(SIVmac239 inoculate, SIVsm stock, SIVsm:C39
sens and
SIVsm:C39
res), two HIV-2 (1682 and 1812) as well as 5 HIV-1
(SF162, 92BR025, 92UG024, CC030 and CC048) viruses. The
magnitude of an individual IgG sample was determined by its
neutralization score defined as log-transformed titers [9]. Log-
transformed titers were calculated by dividing the highest
neutralizing titer values by 100 before applying a log-base 3
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titers below the limit of detection were given a value of 33 to
calculate a neutralization score. The potency score for each
macaque was calculated by summarizing the magnitude (neutral-
ization score) against each virus and then dividing by total number
of viruses tested in Table 2 (n=8). Breadth of an individual IgG
sample was defined by the number of viruses neutralized at a 1:20
dilution.
Isolation and PCR amplification of env from viral RNA
RNA was isolated from plasma samples using the QIAamp
Viral RNA Mini Kit (Qiagen) as per the manufacturer’s protocol.
140 ml plasma or supernatant was used for isolation and RNA was
eluted in a final volume of 40 ml. Viral RNA was amplified in a
one-step RT-PCR reaction using Superscript III One-step RT-
PCR with High Fidelity Platinum Taq (Invitrogen). Reactions
consisted of an RT step of 55uC for one hour, denaturation of two
minutes at 94uC, followed by 40 cycles of PCR of the whole env
gene with SIVF (59-CTG CAT CAA ACA AGT AAG TAT GGG
ATG TCT TGG G-39) and SIVR (59-CAT ATA CTG TCC
CTG ATT GTA TTT CTG TCC CTC-39). When samples gave
no visible band following electrophoresis, a first round of RT-PCR
was carried out using external primers (SIVextF: 59-ATC CTC
TCT CAG CTA TAC CGC C-39 and SIVextR: 59-GAT GAG
TAA GAT GAT GAC TTG GA GGG-39), followed by a second
round of PCR with SIVF and SIVR using Advantage 2
Polymerase mix (Clontech). In order to ensure that all DNA
strands were freshly generated, and hence homoduplexes, purified
PCR product underwent an additional round of PCR with SIVF
and SIVR primers containing an additional CAT ‘identifier tag’
sequence at the 59 end. PCR product (2.7kb) was gel purified using
the QIAquick Gel Extraction Kit (Qiagen) according to the
manufacturer’s protocol.
Cloning and sequencing of env PCR products
Purified PCR product was cloned into the pCRH4-TOPO
vector from the TOPO TA CloningH Kit for Sequencing
(Invitrogen) according to the manufacturer’s protocol. Following
transformation into One-shot TOP10 chemically competent E.coli,
colonies were selected on ampicillin. Colonies were picked and
shipped to Functional Biosciences, Inc, Madison, WI, USA for
sequencing. Plasmid DNA was extracted and sequenced using the
four primers (M13F (59-GTA AAA CGA CGG CCA G -39)
M13R (59- CAG GAA ACA GCT ATG AC-39) SIV_seqF (59-
TGT CAT ATT AGA CAA ATA ATC AAC AC-39) and
SIV_seqR (59-AAT CGA TAC AGT TCT GCC ACC TCT
GC-39).
Sequence assembly
The data was assembled into full-length sequences (contigs)
using a custom scripts that automatically ran pregap4 (http://
staden.sourceforge.net/manual/pregap4_unix_toc.html), extract-
ed open reading frames (ORFS) from the contigs using the
EMBOSS tool getorf [48] and aligned the ORFS (DNA and
protein) using MUSCLE [62]. This approach generated a single
sequence for each clone, spanning the entire env gene. Incomplete
sequences were discarded. Sequence data are available from
GenBank under accession numbers HM800143 to HM800423.
CD4
+ correlation with viral load
The non-parametric Spearman correlation test was used to test
for correlation between CD4
+ T-cell population and viral load.
The different groups of macaques were compared by using the
Mann-Whitney non-parametric test using SPSS statistical soft-
ware. In addition, the data obtained over time were analyzed using
the two-way repeated measures analysis of variance model.
Initial phylogenetic analyses
We used phylogenetic analyses to infer viral evolutionary history
in env, particularly, to distinguish amino acid replacements under
positive selection from those occurring at random. Our initial
phylogenetic analysis checked the quality of the input data, and
then sought to obtain a robust estimate of the best phylogeny,
substitution model and substitution model parameters as a solid
foundation for the later selection and epistasis analyses. During the
phylogeny reconstruction the assembled sequences were aligned in
MUSCLE [62] and inspected visually in Se-Al (A. Rambaut:
http://tree.bio.ed.ac.uk/software/seal). First-pass phylogenetic
reconstruction was carried out in PHYML [63] under the HKY+c
model with empirical base frequencies. This phylogeny was
inspected in FigTree (http://tree.bio.ed.ac.uk/software/figtree)
and all sequences with excessively long branches removed from the
analysis. ModelTest [64–66] (implemented in HYPHY [67] was
used to identify the best-fitting model for the data, by Akaike
information criterion (AIC) and hierarchical analyses. This model
(GTR+c+I) was used in all future analyses wherever possible. The
phylogeny and model parameters for this refined data set were
then iteratively optimised in GARLI [68] http://www.bio.utexas.
edu/faculty/antisense/garli/Garli.html) and PHYML, respective-
ly. Alignment diversity was scored for each site in the nucleotide
and codon alignments using the Shannon entropy index,
implemented in the program Shannon ([69] J.Parker http://
evolve.zoo.ox.ac.uk/evolve/SHiAT.html). Pair-wise divergence
between sequences and the root (SIVmac239) sequence was
calculated in HYPHY under the GTR+c+I model.
Detection of selection
The direction (positive/neutral/negative) and strength of
selection can be inferred from the ratio of the rate of nucleotide
mutations leading to non-synonymous (dN) or synonymous (dS)
amino-acid changes (substitutions). In general, at sites where dN is
much greater than dS positive selection is likely to have occurred.
Conversely, at sites where dN is much less than dS conservation
(negative selection) is inferred. Global (env) and site-wise dN/dS
ratios were estimated from the best available topologies in
HYPHY. The best-supported nucleotide substitution model
identified above (GTR+c+I) was fitted to the data to estimate
the nucleotide states at ancestral nodes in the phylogeny. Next,
site-wise dN/dS ratios and significances were estimated by single
likelihood ancestor counting (SLAC) in HYPHY with ambiguities
in ancestral sequences resolved by averaging and using a single-
parent node structure [67].
Arrival time of positively-selected amino-acid
substitutions
For each animal the earliest time following infection at which
each amino-acid substitution occurred (‘arrival time’) was
reconstructed in following way: we matched the ancestral
sequence inferred at each internal node in the phylogeny with
its mean posterior estimated date of existence; for each site in the
amino-acid alignment, we then calculated the earliest time at
which any amino-acid substitution away from the parental
(SIVmac239) sequence occurred within each macaque’s sub-tree.
Subsequent wild-type reversions were ignored; we grouped amino-
acid substitutions’ arrival times according to whether they
occurred at sites predicted to be subject to positive selection or
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mapped the first occurrence of positively-selected substitutions in
the sub-tree representing each macaque onto the phylogeny
(Figure S4).
Estimating population genetic diversity
Our samples were drawn at three time points (2, 5.5 and 9
months p.i. as well as the parental virus), and consequently do not
evenly cover the entire study period resulting in large confidence
intervals. Therefore, we did not examine temporal fluctuations in
viral diversity directly. Fortunately, Bayesian Markov-chain Monte
Carlo (MCMC) techniques employing the coalescent [70] are able
to exploit temporally-spaced sequence data to estimate ancestral
population genetic diversity (PGD) at all points in time, not just
those time points at which samples were taken. Therefore we have
also analysed the data under a coalescent Bayesian MCMC
analysis in BEAST v1.4.8 [71] using a relaxed molecular clock
model (a model of evolution that in contrast to the strict clock
model (a single substitution rate applied across the phylogeny)
allows substitution rates to vary across the phylogeny) [72] and
constraining the tree so that individual macaques’ sequences
formed exclusive sub-trees (as monophyletic groups). Having
estimated substitution model and mean evolutionary rate param-
eters jointly from this data-set, we then repeated the BEAST
analysis separately for individual animals, fixing these substitution
model and rate parameters for individual animals, this time using
the Bayesian skyline plot reconstruction to estimate ancestral
population sizes. All BEAST MCMC chains were constructed
from 30610
6 states to give 30,000 samples, with 10% discarded
for burn-in (to ensure the MCMC sampler had begun to sample
from the true posterior parameter distributions correctly). Several
chains were run separately to check convergence; traces were
inspected by hand to verify that a 10% burn-in was sufficient and
combined. We estimated the env sequence diversity and absolute
size of the viral population in each animal during the treatment
phase and obtained the sum of PGD estimates (time-integral of
PGD) during the treatment phase.
Structural patterns of SIV evolution
A molecular model of the monomeric SIV gp120 was generated
using the crystal structure of the HIV-1 gp120 (PDB ID 2B4C) and
the SWISS-MODEL protein modeling server [73]. The program
Coot was further used for small localized structural refinements
[74]. The trimeric model of SIV gp120 was created using a
previously published model of the HIV-1 gp120 trimer kindly
provided by Dr Peter D. Kwong and Dr Marie Pancera.
Positively- and negatively-selected sites were mapped on the
gp120 models and potential N-linked glycosylation sites were
identified using the N-GlycoSite prediction tool from the HIV
sequence database (http://www.hiv.lanl.gov/content/sequence/
GLYCOSITE/glycosite.html) [75]. Figures were created using
Pymol (DeLano Scientific LLC, Palo Alto, USA).
Positive selection in hypervariable (V) regions
We investigated the potential disproportionate clustering of
positively-selected substitutions in the hypervariable (V) regions of
the env gene. In order to retain statistical power while allowing for
false positives arising from the large number of hypothesis tests
these data represent, we opted to compare the empirical
distribution of p-values in support of positive selection between
these regions. We calculated empirical cumulative distribution
functions (eCDF) on the confidence measures (p-values) for positive
selection in individual amino acids, both for the whole alignment
and for subsets covering each of the five recognised V regions. The
eCDF function orders the observed p-values and then scores the
cumulative proportion of total observed values that fall into
discrete bins: a series of ranges from 0–1 in small (0.01) increments
(0–0.01, 0.01–0.02, to 1). Larger functions at low p-values indicate
greater significance. The eCDFs were compared to the eCDF for
p-values in the whole env gene using the one-sided Kolmogorov-
Smirnov distribution difference test (Ha:D all.DV).
Correlation between evolutionary and clinical factors
(multivariate analysis)
Animals were assigned ranks based on each of the clinical (viral
load at 6.5 months; CD4
+ T- cell decline up to 6.5 months and
CD4 counts at 6.5 months; NAb breadth and potency) and
evolutionary (diversity; divergence; number of positively-selected
mutations; time-integral of PGD) indicators. A Spearman rank-
correlation was used to determine if there were any relationships
between evolutionary and clinical factors. To control for false-
positives, we employed the multiple test correction procedure used
by Benjamini and Hochberg [44].
Supporting Information
Figure S1 CD4
+ T cells in macaques after SIVmac239 infection.
Kinetic analyses of peripheral blood CD4
+ T cells during
SIVmac239 infection. CD4 counts are depicted longitudinally
for each animal (LC; green, TC; blue and NC; red). Tenofovir
treatment period is indicated by shaded area.
Found at: doi:10.1371/journal.ppat.1001084.s001 (0.41 MB TIF)
Figure S2 Heterologous neutralization of HIV-2. Purified IgG
obtained from plasma samples 14 months post-inoculation were
titrated and analyzed for neutralization of HIV-2 1812 (A) and
HIV-2 1682 (B). Neutralization profiles of NC (animal 3, red) and
TC (animals 1, 5, 8, 11 blue) as well as LC (animals 2, 4, 6, 7, 9,
10, 12, green) are shown. Values are means of two independent
assays. Assay cut-off was 30% as indicated by line.
Found at: doi:10.1371/journal.ppat.1001084.s002 (0.40 MB TIF)
Figure S3 Sequence positions of mutations in re-isolates from
NC3. Env sequences from virus re-isolated from macaques 3 at 4.5
months p.i. were compared with that of SIVmac239 in order to
identify escape mutations that could account for the observed
changes in neutralization sensitivity. NC3 sequences displayed a
number of sequence changes including V67M, A417T and
R751G. Sequences obtained from NC3 at 4.5 months (neutral-
ization resistant) and 9 months (neutralization sensitive) were also
compared. Escape mutations that confer resistance were still
present suggesting a broadening of the NAb response at the later
time point.
Found at: doi:10.1371/journal.ppat.1001084.s003 (0.39 MB TIF)
Figure S4 Phylogeny reconstruction and arrival times of
significant positively-selected codon substitutions. Phylogeny
reconstruction: Maximum clade credibility (MCC) tree of 281
SIV env sequences (12 hosts) plus inoculate (SIVmac239). MCC
tree resolved from posterior set of 9000 trees (PST) sampled from
the posterior distribution in BEAST. Sequences from each host
constrained to be monophyletic. Model parameters: Substitution -
HKY85+gamma (4 rate categories); demographic - exponential
growth; molecular clock type - uncorrelated lognormal distribution
(UCLN; ‘relaxed’ clock); branch lengths in average nucleotide
substitutions. Sub-trees corresponding to individual macaques are
shown in various colours. Arrival times: Starred (‘*’) nodes
represent the earliest estimated arrival time significantly positive-
ly-selected codon substitution (neutrally-selected substitutions and
reversions not shown; see Methods).
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Figure S5 Empirical cumulative density functions (eCDF) of p-
values for positively-selected amino-acid substitutions. The eCDF
is a binning function that scores the proportion of total data points
(vertical axis) of equal or lesser p with increasing values of p from 0
to 1 (horizontal axis). Low-valued (significant p) data sets are
expected to plateau early, while high-valued (not significant p) data
sets will plateau late. Black: all env sites; red V1; blue V2; green V3;
brown V4, and grey V5.
Found at: doi:10.1371/journal.ppat.1001084.s005 (0.14 MB TIF)
Table S1 Number of env sequences obtained from plasma
samples and re-isolated virus for macaques 1–12.
Found at: doi:10.1371/journal.ppat.1001084.s006 (0.04 MB
DOC)
Table S2 Positive and negative selection in SIV env.
Found at: doi:10.1371/journal.ppat.1001084.s007 (0.15 MB
DOC)
Table S3 Epistasis in SIV env.
Found at: doi:10.1371/journal.ppat.1001084.s008 (0.09 MB
DOC)
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